Universal CAR-T cells for acute myeloid leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a universal CAR-T cell therapy for acute myeloid leukemia (AML), a type of blood cancer. The treatment uses specially engineered immune cells to target leukemia cells with certain markers, and the trial aims to see if it is safe and effective for patients whose leukemia has not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You or your child must be at least 6 months old.
- A lab test must show your leukemia cells have at least one of these markers: CLL-1, CD123, CD38, or CD33.
- You must be generally able to care for yourself (performance score above 80) and expected to live more than 3 months.
- Your heart, lungs, kidneys, and liver must be working well enough (e.g., heart pumping function 50% or more, oxygen level 90% or higher, and kidney/liver tests within limits).
- Your hemoglobin level must be at least 80 g/L.
- You must not have an active uncontrolled infection, HIV, or hepatitis C.
- You cannot be pregnant or breastfeeding, and must not have had gene therapy before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy that uses your own cells, modified to attack leukemia cells in multiple ways. It aims to find a safe and effective dose for people with acute myeloid leukemia who have not responded to other treatments.
This study tests a new treatment using your own immune cells, modified to find and kill leukemia cells that have a marker called CLL1. It is for people with AML that has come back or not responded to standard care, and it may be followed by a stem cell transplant.
This study tests a new kind of immunotherapy called CAR-T cells that are engineered to find and attack leukemia cells carrying certain markers (CD33, CD123, or CLL-1). The treatment is given in two steps, aiming to kill cancer cells more effectively and possibly with fewer side effects.
This study tests a new CAR-T cell therapy that targets two proteins, CLL1 and CD38, on leukemia cells. It is designed for people whose acute myeloid leukemia has returned or not responded to treatment.
This trial tests a new type of immune cell therapy (CAR T cells) for people with acute myeloid leukemia (AML) that has come back or not gone away after treatment. The therapy is designed to find and attack leukemia cells that have a specific marker called CD371.
This trial tests an experimental treatment using your own immune cells (called CAR-T cells) that are specially designed to find and destroy leukemia cells that have a specific marker called CD123. It is for people with acute myeloid leukemia (AML) that has not responded to treatment or has returned, and who have limited other options.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.